Figure 4 | Scientific Reports

Figure 4

From: Transcriptomic and proteomic analysis of tumor suppressive effects of GZ17-6.02 against mycosis fungoides

Figure 4

GZ17-6.02 suppresses the CXCR4/CXCL12 axis. (A) CXCR4 expression in control and GZ17-6.02 treated HH cells. (B) CXCR4 expression in control and GZ17-6.02 treated MyLa cells. (C) GSVA for CXCL12 signaling pathway in control and GZ17-6.02 treated HH and MyLa cells. (D) Hallmark EnrichR enrichment analysis of phospho-proteomic data showing suppression of CXCR4 signaling and downstream pathways in GZ17-6.02 treated HH cells. (E) Hallmark EnrichR enrichment analysis of phospho-proteomic data showing suppression of CXCR4 signaling and downstream pathways in GZ17-6.02 treated MyLa cells. *p < .05; ***p < .001; ctrl, control; GSVA, gene set variation analysis; GZ, GZ17-6.02.

Back to article page